Venlafaxine vs Duloxetine: Comparing the Two Main SNRIs

Venlafaxine (Effexor XR) and duloxetine (Cymbalta) are two SNRIs that are both FDA-approved for depression and generalized anxiety disorder in adults. The clearest differences are in their other approved uses, how much attention each needs for blood pressure, the liver, and stopping. Duloxetine is FDA-approved for several chronic pain conditions and for anxiety in children from age 7, but should not be prescribed with substantial alcohol use or chronic liver disease. Venlafaxine XR is approved for social anxiety and panic disorder, raises blood pressure in a dose-related way, and has one of the harder discontinuation profiles among antidepressants.

Large trial analyses cannot tell you which one will work better for you. The choice usually turns on pain, blood pressure, liver health, alcohol use, other medications and how likely you are to miss doses, and it is one to make with your prescriber.

Venlafaxine and duloxetine at a glance

How they compare for depression and anxiety

Both block the reuptake of serotonin and norepinephrine. In the 2018 network meta-analysis of 522 trials and 116,477 adults, every antidepressant studied beat placebo for major depression, and differences between drugs were smaller when placebo-controlled trials were included. In head-to-head trials, venlafaxine was among the more effective drugs; on acceptability, measured as stopping treatment for any reason, both duloxetine and venlafaxine were among those with the highest dropout rates. The certainty of that evidence was rated moderate to very low, so these rankings are a weak guide for any one person.

For anxiety, both are FDA-approved for generalized anxiety disorder in adults. Venlafaxine XR is also approved for social anxiety disorder and panic disorder, which duloxetine is not. An approval reflects which trials a manufacturer ran; the absence of one is not proof that duloxetine fails in those conditions. For how SNRIs fit against SSRIs and bupropion more generally, see how a first antidepressant is chosen, and for the wider anxiety picture, anxiety treatment options compared.

When pain is part of the picture

This is duloxetine's clearest advantage. It is FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain in adults, and for juvenile fibromyalgia from age 13. Venlafaxine XR carries no FDA-approved pain indication, so using it for pain is off-label. Off-label use can be reasonable, but when depression or anxiety comes with one of those pain conditions, one medication with approval for both is an obvious starting point for the conversation.

When pain and low mood occur together, it helps to treat both deliberately rather than expecting one pill to settle everything. Non-drug pain care, such as physical therapy, activity pacing and psychotherapy, is worth discussing alongside the drug choice with whoever manages your pain.

Blood pressure: who needs closer monitoring

Venlafaxine's label describes dose-related increases in systolic and diastolic blood pressure in controlled trials, along with cases of sustained hypertension, and tells prescribers to control pre-existing hypertension before starting and to monitor blood pressure regularly. Across its clinical studies, 1.4% of people on venlafaxine XR had a diastolic rise of at least 15 mm Hg to 105 mm Hg or higher, compared with 0.9% on placebo. The label also notes that too few patients took more than 300 mg a day in trials to fully evaluate sustained blood pressure increases at those doses.

Duloxetine also calls for blood pressure checks before and during treatment, but the average change in trials was small: mean increases of 0.5 mm Hg systolic and 0.8 mm Hg diastolic, compared with small decreases on placebo. Duloxetine's label also warns about the opposite problem: orthostatic hypotension, falls and fainting, most often in the first week or after dose increases, and more likely in people taking blood pressure medicines.

What this means in practice

• If you have high blood pressure, especially if it is not yet controlled, venlafaxine's label calls for controlling it before starting and for caution and regular checks during treatment.
• If you are prone to dizziness on standing or take medicines that lower blood pressure, duloxetine's orthostatic and fall risks deserve attention.
• Either way, a home blood pressure cuff and a simple log make follow-up visits more useful. This article on psychiatric medications and cardiovascular risk covers the broader picture.

Liver, kidneys and alcohol

Duloxetine carries a specific liver warning. Its label reports hepatic failure, sometimes fatal, and cases of hepatitis with transaminase elevations more than twenty times the upper limit of normal. Because duloxetine and alcohol may interact to cause liver injury, the label says duloxetine should not be prescribed to people with substantial alcohol use or evidence of chronic liver disease, and should be avoided in cirrhosis. It should also be avoided in severe kidney impairment, with a GFR below 30 mL/minute.

Venlafaxine does not carry the same liver warning, though its label calls for lower doses in liver and kidney impairment. For anyone who drinks heavily or has liver disease, this difference alone often settles the choice. Be candid with your prescriber about alcohol, and ask whether liver tests make sense before or during treatment in your case; psychiatric medications and alcohol explains why honesty here protects you.

Stopping: the discontinuation difference

Both labels describe discontinuation symptoms such as dizziness, nausea, headache, irritability, insomnia and sensory disturbances, and both recommend a gradual reduction rather than abrupt stopping. Venlafaxine's label goes further. It says symptoms became more frequent with higher doses and longer treatment, that postmarketing reports describe protracted and severe symptoms, and that in some patients discontinuation may need to occur over several months.

The short half-life is part of the reason: venlafaxine's elimination half-life is about 5 hours and its active metabolite's about 11 hours, so levels fall quickly after a missed dose. A 2024 meta-analysis of 79 studies found that venlafaxine and desvenlafaxine were among the antidepressants associated with more frequent discontinuation symptoms, and among those linked to more severe symptoms. The same analysis estimated that, overall, 31% of people stopping an antidepressant had at least one symptom compared with 17% stopping placebo.

Duloxetine's half-life is about 12 hours, and its own trials also documented discontinuation symptoms after both abrupt and tapered stopping. It is not a "free" exit, only a somewhat less notorious one. If you often miss doses or travel across time zones, raise that before starting. Plans for coming off are covered in discontinuing long-term medication and, for a change of drug, switching antidepressants.

Side effects and interactions

Like other serotonergic antidepressants, both can contribute to serotonin syndrome with other serotonergic drugs and raise bleeding risk with NSAIDs, aspirin or anticoagulants, and both labels warn about angle-closure glaucoma in people with untreated narrow angles. Duloxetine is a moderate CYP2D6 inhibitor; given with desipramine it tripled desipramine exposure, so drugs with a narrow margin processed by that enzyme need care.

Overdose risk differs too. Venlafaxine's label notes retrospective studies associating venlafaxine overdose with more fatal outcomes than SSRI overdose, though fewer than tricyclics, and that people prescribed venlafaxine had more pre-existing suicide risk factors, so how much reflects the drug itself is unclear. It is worth raising with your prescriber if overdose risk is a concern.

Children, teens and older adults

Neither drug is FDA-approved for depression in young people. Duloxetine's label reports that two 10-week trials in 800 patients aged 7 to 17 with depression did not show efficacy, while its approvals for pediatric GAD from age 7 and juvenile fibromyalgia from age 13 stand. Effexor XR is not approved for use in pediatric patients. For a teen's depression, see our parent's guide.

In older adults, the practical concerns are blood pressure with venlafaxine and dizziness, orthostatic drops and falls with duloxetine, along with low sodium (hyponatremia), which both labels list as a risk, particularly in older patients. The venlafaxine label recommends no dose adjustment for age alone, though kidney or liver impairment, which is more common with age, may call for one.

Matching the drug to the situation

Common mistakes with SNRIs

• Skipping doses on busy days. With venlafaxine especially, the label links abrupt stopping or dose reduction to symptoms such as dizziness, irritability and electric-shock-like sensations. Pill organizers and phone reminders are worth the bother.
• Stopping because you feel better. Feeling well may mean the medication is working, not that it is no longer needed. When and how to stop is a planned conversation.
• Not mentioning alcohol. Duloxetine's liver warning makes an accurate drinking history essential.
• Adding over-the-counter products without asking. Both labels list migraine triptans, tramadol, tryptophan and St. John's wort among the serotonergic products that raise the risk of serotonin syndrome. A pharmacist can check combinations quickly.
• Ignoring early blood pressure changes. A few home readings in the first weeks, and after each dose increase, catch problems before they matter.
• Judging too early or too late. Giving up after a few days may be too soon, while staying for many months on a dose that is not helping wastes time. Agree on a review point at the start.
• Treating pain and mood as separate projects. When one drug is meant to help both, track both, so you and your prescriber can tell which part is working.

If side effects are making daily life harder, write down what happens and when, and bring it to the next visit or call between visits. Many problems have practical fixes, such as taking the dose with food, changing the time of day, or adjusting the dose, and these are decisions to make with the prescriber rather than alone.

Questions to ask your prescriber

• Do my blood pressure readings, liver tests or kidney function change which of these is safer for me?
• If pain is one of my problems, which drug addresses both, and what non-drug pain care should run alongside it?
• How often should my blood pressure be checked, and should I keep a home log?
• What would a taper look like if we stop later, and what should I do if I miss a dose?
• Could any of my other medicines or supplements interact with this one?
• If this does not help enough, is the next step a dose change, a switch, or adding something? (See augmentation options.)

Do not start, stop or adjust either medication on your own; discontinuation symptoms with SNRIs can be significant, and a planned taper is safer. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

How the practice handles SNRI decisions

At Dr. Lewis's practice, psychiatric evaluation and medication management are offered alongside psychotherapy, coaching, lab testing, and nutrition and lifestyle psychiatry, so blood pressure, lab results and other health conditions can be considered together with the prescription. You can read about medication management and lab testing at the practice, or begin with a free discovery call. Related comparisons are gathered in the Choosing Psychiatric Care guide.

Frequently asked questions

Can I open the capsule if I have trouble swallowing pills?

It depends on the drug. The venlafaxine XR label allows the capsule to be opened and the contents sprinkled on a spoonful of applesauce and swallowed without chewing, while the duloxetine label says to swallow the capsule whole and not open it, because that could affect its coating. Ask your pharmacist before altering any capsule.

Can I switch from venlafaxine to duloxetine to get off venlafaxine more easily?

Prescribers sometimes cross over from one antidepressant to another during a difficult taper, but there is no single right method. The plan depends on your dose, how long you have taken it and how you reacted to previous dose changes. Work it out with your prescriber; see switching antidepressants.

Does duloxetine help nerve pain even if I am not depressed?

Yes. Duloxetine is FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia and chronic musculoskeletal pain in adults, independent of depression. For pain alone, a primary care doctor, neurologist or pain specialist usually manages it.

Will an SNRI raise my blood pressure if mine is normal?

It can. Venlafaxine raised blood pressure in a dose-related way in trials, while duloxetine's average change was small, and both labels call for blood pressure checks before and during treatment. Report headaches, a pounding pulse or high home readings to your prescriber.

Which one causes less sexual dysfunction?

Both raised sexual dysfunction rates over placebo in a meta-analysis. If sexual side effects matter a great deal to you, discuss alternatives such as bupropion or mirtazapine, which did not differ significantly from placebo in that analysis.

How long before I know whether it is working?

Some change may show within the first few weeks, but how long a fair trial lasts, and at what dose, is set by your prescriber. Tracking symptoms with a tool such as the PHQ-9 helps; see PHQ-9 and GAD-7 scores explained.

Sources

1. EFFEXOR XR (venlafaxine extended-release capsules) prescribing information. Viatris Specialty LLC via DailyMed (U.S. National Library of Medicine), 2025. dailymed.nlm.nih.gov
2. Duloxetine delayed-release capsules prescribing information. Ajanta Pharma USA (Hawaii Repack listing) via DailyMed (U.S. National Library of Medicine), 2026. dailymed.nlm.nih.gov
3. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet (Cipriani et al.), 2018. pubmed.ncbi.nlm.nih.gov
4. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry (Henssler et al.), 2024. pubmed.ncbi.nlm.nih.gov
5. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology (Serretti and Chiesa), 2009. pubmed.ncbi.nlm.nih.gov

Educational information, not medical, tax or legal advice. Decisions about diagnosis, medication and treatment belong with a clinician who knows your history.